Top Page
Paradigm Biopharmaceuticals
(Sydney:PAR)
Paradigm Biopharmaceuticals (PAR) vs. iShares MSCI Australia ETF (EWA)
Paradigm Biopharmaceuticals Business Overview & Revenue Model
Paradigm Biopharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.12K | 52.12K | 65.80K | 46.76K | 79.22K | 20.55K |
| Gross Profit | -48.42K | -19.89K | 56.81K | -18.83K | -64.53K | -78.59K |
| EBITDA | -25.24M | -25.25M | -64.54M | -59.06M | -46.82M | -42.40M |
| Net Income | -18.77M | -18.77M | -58.65M | -51.91M | -39.25M | -34.30M |
Balance Sheet | ||||||
| Total Assets | 24.57M | 24.57M | 27.39M | 67.07M | 50.69M | 84.79M |
| Cash, Cash Equivalents and Short-Term Investments | 16.82M | 16.82M | 17.87M | 56.38M | 39.72M | 71.08M |
| Total Debt | 5.48K | 5.48K | 239.33K | 341.67K | 616.67K | 751.84K |
| Total Liabilities | 3.39M | 3.39M | 3.58M | 13.39M | 8.38M | 6.52M |
| Stockholders Equity | 21.18M | 21.18M | 23.81M | 53.68M | 42.31M | 78.27M |
Cash Flow | ||||||
| Free Cash Flow | -15.99M | -15.99M | -65.94M | -45.19M | -32.21M | -34.96M |
| Operating Cash Flow | -15.99M | -15.99M | -65.94M | -45.19M | -32.21M | -34.93M |
| Investing Cash Flow | 46.20K | 46.20K | 0.00 | 0.00 | 0.00 | 668.37K |
| Financing Cash Flow | 14.99M | 14.99M | 28.18M | 62.53M | 70.12K | 1.00M |
Paradigm Biopharmaceuticals Technical Analysis
Paradigm Biopharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$114.16M | -1.11 | -83.09% | ― | ― | 55.94% | |
46 Neutral | AU$154.27M | -6.84 | -81.03% | ― | -20.79% | 73.98% | |
44 Neutral | AU$196.64M | -7.55 | ― | ― | ― | 0.66% | |
44 Neutral | AU$111.71M | -13.24 | -47.98% | ― | 700.00% | 26.88% | |
41 Neutral | AU$97.88M | -5.26 | -42.68% | ― | ― | 63.46% |
Paradigm Biopharmaceuticals Corporate Events
Paradigm Biopharmaceuticals has confirmed it has enrolled or randomised enough patients to meet the 25% recruitment threshold in its pivotal global Phase 3 PARA_OA_012 trial of injectable pentosan polysulfate sodium for knee osteoarthritis, with some participants scheduled to begin dosing after the holiday period to safeguard protocol compliance over the six-week regimen. The company reports strong screening activity, boosted by a targeted Medimark-led outreach campaign in Australia that has generated thousands of pre-screened leads, and expects recruitment momentum to accelerate as more sites, including new centres in Moldova and Hong Kong, become fully active, keeping interim analysis timing for mid-2026 and full primary endpoint read-out in late 2026 in line with prior guidance, a key marker for the program’s progress and future commercial prospects.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals Limited announced the successful passing of all resolutions during its 2025 Annual General Meeting. Key resolutions included the adoption of the remuneration report, re-election of a director, approval of convertible notes issuance, and renewal of takeover provisions. These decisions are expected to strengthen the company’s governance and financial strategies, potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has issued a Cleansing Notice related to the issuance of convertible notes, allowing for the conversion of these notes into fully paid ordinary shares that can be sold to retail investors without further disclosure. The company has secured commitments for up to US$27 million through a Convertible Securities Agreement with Obsidian Global GP LLC, with an initial drawdown of US$7 million and a recent additional drawdown of US$5 million. This financial maneuver is expected to impact the company’s operations by providing capital for growth and enhancing its market positioning.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals Limited announced the issuance of 5,000,000 unquoted convertible notes as part of a previously disclosed transaction. This move is part of the company’s strategic financial operations, potentially impacting its capital structure and providing additional resources for its ongoing projects.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has completed a US$5 million drawdown under its US$27 million Convertible Note Facility with Obsidian Global Partners. This funding will support the company’s global Phase 3 clinical trial for knee osteoarthritis, as it expands operations with new trial sites in Europe and Asia. The drawdown ensures Paradigm remains well-capitalized during this period of increased clinical activity, with US$15 million still available for future needs. The company maintains disciplined financial management to align investments with trial progress, ensuring funding through key milestones, including an interim analysis in mid-2026.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paul Rennie, a significant shareholder in Paradigm Biopharmaceuticals, has ceased to be a substantial holder as of October 30, 2025, due to dilution from the conversion of convertible notes. This change affects over 20 million ordinary shares, impacting the company’s shareholder structure and potentially its market positioning.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has engaged Nordic Bioscience Clinical Development (NBCD) A/S as a complementary contract research organization to support its pivotal Phase 3 clinical trial for knee osteoarthritis. This collaboration will activate four new clinical sites in Hong Kong and Moldova, enhancing the trial’s global footprint and aligning with Hong Kong’s new ‘1+’ regulatory pathway. The strategic expansion is expected to bolster Paradigm’s commercial readiness and data robustness, with recruitment set to commence in January 2026. The initiative aims to strengthen Paradigm’s scientific and operational foundations, offering potential regulatory and commercial flexibility in the Greater Bay Area and improving data quality with diverse patient populations.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals Limited announced the issuance of 3,000,000 unlisted options as part of a previously disclosed transaction. These securities are unquoted and not intended for quotation on the ASX, reflecting the company’s strategic financial maneuvers to support its ongoing operations and growth initiatives.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals announced the details of its upcoming annual general meeting, scheduled for November 19, 2025, to be held both in-person and virtually. Shareholders are encouraged to participate by submitting proxy forms and questions in advance, with the company providing online resources to facilitate engagement. This move reflects the company’s commitment to shareholder engagement and transparency, potentially impacting its operational strategies and stakeholder relations positively.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals Limited has announced the quotation of 11,714,207 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 8, 2025. This move is part of the company’s strategic efforts to enhance its financial flexibility and support its ongoing development projects, potentially strengthening its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has reached a significant milestone in its Phase 3 clinical trial for iPPS, a treatment for knee osteoarthritis, by dosing participants in both the United States and Australia. The trial, which aims to evaluate the efficacy and safety of iPPS, has shown improved screening results due to refined eligibility criteria guided by the FDA. With nearly all sites expected to be activated by the end of October, the company is on track to meet its enrolment targets and deliver an interim analysis by mid-2026, potentially impacting its market position and stakeholder value.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.